Every reason behind the verdict rather than the headline one — which of your certifications match, how much runway is left, whether the work is your size, and what we would need to know to sharpen it.
Written against this notice and what you have told us about your company. Anything we do not know is marked [NEEDS INPUT] in the draft rather than guessed at — read it before you send it.
Start a free trial to draft these. Nothing is sent to an agency on your behalf, ever — you get a document to review, edit and submit yourself.
Sources Sought response
A complete draft response — capability statement, relevant past performance, business size and socioeconomic status, and answers to the agency's specific questions.
Questions to submit
Genuine ambiguities and requirements that disadvantage a smaller bidder, drafted as questions you can submit before the Q&A deadline.
Past performance write-ups
Which of your prior awards best match this requirement, and draft write-ups in the format the agency asked for.
Solicitation details
Solicitation number
S-195061
Notice type
Special Notice
NAICS
541714
Product service code
AJ13
Set-aside
No Set aside used
Posted
2026-06-15
Response deadline
Dec 16, 2026, 12:00 AM UTC
Place of performance
Los Alamos, NM
Contracting contact
licensing@lanl.gov
Market intelligence
Account requiredWho wins this work, and what it pays
Comparable awards under NAICS 541714 at this agency — the incumbent, what they were paid, when their period of performance ends, and the real pricing distribution rather than the headline number. From public federal award records.
DC Recruiter: Broad-Spectrum Immune Enhancer from scientists at Los Alamos National Laboratory offers a differentiated approach to multi-pathogen infection prevention by using a self-assembling peptide nanofiber to recruit and activate dendritic cells (DCs), the immune system’s natural sentinels. Unlike pathogen-specific vaccines or therapeutics, it is designed to help trigger an early immune response regardless of the infecting agent. Its needle-free, spray-friendly concept adds practicality. The Challenge: DC Recruiter addresses a persistent and highly consequential gap in infection management: the need for a rapid, broadly effective way to stimulate immune defense before the specific pathogen is known. In many exposure scenarios, the body encounters a threat before clinicians can identify the cause, and that delay can reduce the effectiveness of conventional interventions. Current vaccines, antibiotics and antivirals are generally designed to act against a known target, which limits their usefulness when exposure is unexpected, diagnosis is delayed or the pathogen is unfamiliar. That limitation creates a clear unmet need for a fast-acting, broad-spectrum approach that can be deployed early, with minimal complexity, and in settings where rapid response matters most, including outbreak situations, field environments and other high-risk conditions. Problems Solved: DC Recruiter solves this problem by using a specific peptide selected to bind to dendritic cells. By leveraging a self-assembling peptide nanofiber platform, the technology is designed to help “wake up” immune surveillance early, before infection can progress unchecked. Rather than relying on a treatment matched to one virus or bacterium, it creates the potential for broad-spectrum immune support across many different infectious threats. Its ability to provide broad-spectrum immune support makes it especially compelling for situations where time is critical and conventional options may be too specific, too slow or too late to provide immediate protection. The needle-free, spray-friendly concept also adds practical value by supporting easier administration and broader accessibility, strengthening its fit for real-world use cases that demand rapid, flexible deployment. Key Advantages: Helps the body respond faster after exposure to an infection Works in a broad, pathogen-agnostic way rather than against just one germ Targets dendritic cells, which help alert and activate the immune system May be useful when the exact cause of infection is not yet known Could be helpful in outbreak, emergency, or high-risk settings Has the potential to be easier to use because it is designed as a needle-free spray Market Applications: Infectious Disease Prevention (early-response immune support, broad-spectrum protection) Outbreak Response and Public Health (rapid deployment, exposure mitigation) Defense and National Security (force protection, biological threat preparedness) Consumer Health and Wellness (easy-to-use immune support, potential spray format) Pharmaceuticals and Biotech (next-generation immunomodulation, platform development) Emergency Preparedness (first-response tools, high-risk exposure settings) Development Status: TRL 3 US Patent pending LA-UR-26-24915 LANL Tech Partnerships: Unlock the Innovative Potential Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products. LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov. Note: This is not a call for external services for the development of this technology. https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology m.lanl.gov/tech-search
Contact
Point of contact
Caleb Ledgerwood
Role
not stated on this notice — SAM publishes a role for only about 5% of them, so this may be a contract specialist rather than the contracting officer
Email
licensing@lanl.gov
Secondary
licensing@lanl.gov
Submit questions
Ambiguities and requirements worth clarifying, written as questions you can send before the deadline.
Opens in your own mail client, addressed and with a subject line — you write the message. GovSprint never sends anything on your behalf.
Emails open in your mail client and are sent from your address, so the reply comes back to you and the exchange stays yours. Confirm the correct channel and any question deadline on the notice before sending — many solicitations require questions in a specific way.
